leisure time -WSS

leisure time

author：focus 2025-10-02 00:53:49 - browse：62548

Adam's take main illustration — Molly Ferguson/STAT

Roivant Sciences’ Matt Gline might be this year’s best biopharma CEO, and other thoughts about Monday’s blockbuster deal with Roche — like, why the heck did Roivant’s stock trade down?

Gline created $5 billion from $50 million — in less than one year.Regular readers know that every December, I choose a best biopharma CEO. It’s a subjective award, but deal-making acumen, management skills, and delivering shareholder value are important measuring sticks. It’s still too early to call this year’s contest, but Gline is a front-runner.

Last December, Roivant essentially acquired an experimental treatment for inflammatory bowel disease called RVT-3101 from Pfizer for $45 million and then spent another $5 million to position the drug for future Phase 3 studies. Less than a year later, Roivant flipped the drug to Roche for at least $7.1 billion.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Affirmative action in medical school literally saved lives
Next article： Vertex non

Wikipedia

hotspot

WSS

Flu vaccine offering decent levels of protection this winter, new data show

Flu vaccine offering decent levels of protection this winter, new data show

FogPharma raises $145 million in rare Series E round

An inside look at PIPEs, biotech's buzzy new financing tool

House looks to weaken Medicare negotiation

Abortion pill mifepristone to soon be dispensed at CVS, Walgreens

focus

leisure time

explore

New Eli Lilly Alzheimer’s data poses Medicare coverage conundrum

Wegovy leads to weight loss. Can it treat depression, too?

How one medical school became remarkably diverse

10 reasons why health care startups fail

Malaria cases in Florida and Texas: Here’s what you need to know

Health Care Service Corp to buy Cigna Medicare Advantage plans

Psychedelics group wrestles with new pharma identity

Kale crackers and hibiscus tea: My five days on a 'fasting diet'

United colonoscopy coverage change 'may cost lives,' doctors say

Clinical trials giant ICON acquires HumanFirst

hotspot

Philips to halt sales of sleep apnea machines in U.S.

Bernie Sanders is gearing up to subpoena pharma CEOs

An inside look at PIPEs, biotech's buzzy new financing tool

Kale crackers and hibiscus tea: My five days on a 'fasting diet'

Readout Newsletter: Ironwood, Pfizer, FogPharma updates

RSV vaccines may be linked to small increased risk of developing GBS

Wikipedia

focus

hotspot

Wikipedia